Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists

Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers

(2020) Bahareh Kashani et al.   IMMUNOLOGIC RESEARCH

Immunotherapy in sepsis - brake or accelerate?

(2020) Folkert Steinhagen et al.   PHARMACOLOGY & THERAPEUTICS

TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes

(2019) Xiaohong Cen et al.   Advanced Science

TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition

(2019) Zahra Zandi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy

(2019) Tuan Hiep Tran et al.   Acta Biomaterialia

The anticancer effect of the TLR4 inhibition using TAK‐242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer

(2019) Zahra Zandi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Paeonol antagonizes oncogenesis of osteosarcoma by inhibiting the function of TLR4/MAPK/NF-κB pathway

(2019) Jianguo Zhou et al.   ACTA HISTOCHEMICA

Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid)

(2019) Bahareh Kashani et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research

(2019) David C. McGowan   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy

(2018) Rui Kuai et al.   JOURNAL OF CONTROLLED RELEASE

Structure-based discovery of a specific TLR1–TLR2 small molecule agonist from the ZINC drug library database

(2018) Zhipeng Chen et al.   CHEMICAL COMMUNICATIONS

Recent clinical trends in Toll-like receptor targeting therapeutics

(2018) Muhammad Ayaz Anwar et al.   MEDICINAL RESEARCH REVIEWS

Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword

(2017) Marion Dajon et al.   IMMUNOBIOLOGY

Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals

(2017) Mallenahally Kusha Vidya et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)

(2017) W. H. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent progress in the development of Toll-like receptor (TLR) antagonists

(2016) Mahesh Chandra Patra et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Vaccine adjuvants as potential cancer immunotherapeutics

(2016) Burcu Temizoz et al.   INTERNATIONAL IMMUNOLOGY

Oncolytic viruses as immunotherapy: progress and remaining challenges

(2016) Laure Aurelian   OncoTargets and Therapy

Comparative and parallel genome-wide association studies for metabolic and agronomic traits in cereals

(2016) Wei Chen et al.   Nature Communications

Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia

(2016) H. Ureshino et al.   Cancer Immunology Research

CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway

(2015) Yiting Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337)

(2015) G. N. Dietsch et al.   CLINICAL CANCER RESEARCH

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

(2015) Burghardt Wittig et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703.

(2015) David Cunningham et al.   JOURNAL OF CLINICAL ONCOLOGY

Combinatorial Photothermal and Immuno Cancer Therapy Using Chitosan-Coated Hollow Copper Sulfide Nanoparticles

(2014) Liangran Guo et al.   ACS Nano

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

(2014) David A. Smith et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist

(2014) Abu-Baker M. Abdel-Aal et al.   CHEMBIOCHEM

A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or Lymphoma

(2014) D. W. Northfelt et al.   CLINICAL CANCER RESEARCH

Toll-like receptor agonists: a patent review (2011 – 2013)

(2014) Waleed M Hussein et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Vaccine adjuvant uses of poly-IC and derivatives

(2014) Karen AO Martins et al.   Expert Review of Vaccines

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

(2014) Hans-Joachim Schmoll et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

(2014) Manisha Singh et al.   JOURNAL OF IMMUNOLOGY

N-Tetradecylcarbamyl Lipopeptides as Novel Agonists for Toll-like Receptor 2

(2014) Marian M. J. H. P. Willems et al.   JOURNAL OF MEDICINAL CHEMISTRY

Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation

(2014) James Q. Wang et al.   Frontiers in Immunology

Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis

(2013) M Reeh et al.   BRITISH JOURNAL OF CANCER

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

(2013) A. Marabelle et al.   CLINICAL CANCER RESEARCH

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants

(2013) John P Vasilakos et al.   Expert Review of Vaccines

TLR agonists: our best frenemy in cancer immunotherapy

(2013) Sabina Kaczanowska et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The Yin and Yang of Toll-like receptors in cancer

(2013) J-P Pradere et al.   ONCOGENE

Victories and deceptions in tumor immunology

(2013) Guido Kroemer et al.   OncoImmunology

Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts

(2012) Giorgio Trinchieri   Annual Review of Immunology

Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense

(2012) Shaherin Basith et al.   ARCHIVES OF PHARMACAL RESEARCH

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

(2012) P. Sabbatini et al.   CLINICAL CANCER RESEARCH

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+T-cell responses in melanoma patients

(2012) Simone M. Goldinger et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

A Novel Bitriazolyl Acyclonucleoside Endowed with Dual Antiproliferative and Immunomodulatory Activity

(2012) Yi Xia et al.   JOURNAL OF MEDICINAL CHEMISTRY

An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance

(2012) Vincenzo Cerullo et al.   MOLECULAR THERAPY

A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

(2012) David R. Strayer et al.   PLoS One

An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

(2012) Huagang Zhang et al.   PLoS One

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A

(2012) Stacie L. Lambert et al.   PLoS One

Structural Basis of TLR5-Flagellin Recognition and Signaling

(2012) S.-i. Yoon et al.   SCIENCE

Targeting pattern recognition receptors in cancer immunotherapy

(2012) Nadège Goutagny et al.   Targeted Oncology

CpG plus radiotherapy: a review of preclinical works leading to clinical trial

(2012) Kathy A. Mason et al.   Frontiers in Oncology

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV

(2011) J. F. Bergmann et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis

(2011) Friedrich Horak   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Toll-Like Receptors: Cost or Benefit for Cancer?

(2010) T. Matijevic et al.   CURRENT PHARMACEUTICAL DESIGN

Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients

(2010) Daniel E. Speiser et al.   JOURNAL OF IMMUNOTHERAPY

TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules

(2010) N. Matsunaga et al.   MOLECULAR PHARMACOLOGY

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Increasing the Antigenicity of Synthetic Tumor-Associated Carbohydrate Antigens by Targeting Toll-Like Receptors

(2009) Sampat Ingale et al.   CHEMBIOCHEM

The potential use of toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents

(2009) Amani Makkouk et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Inflaming metastasis

(2009) Alberto Mantovani   NATURE

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

(2009) Sunhwa Kim et al.   NATURE

Functionally Active Toll-Like Receptor 3 on Human Primary and Metastatic Cancer Cells

(2009) T. Matijevic et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Ampligen: A potential toll-like 3 receptor adjuvant for immunotherapy of cancer

(2009) B. Jasani et al.   VACCINE

Vaccines for lymphomas: Idiotype vaccines and beyond

(2008) Roch Houot et al.   BLOOD REVIEWS

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

Functional diversification of the toll-like receptor gene family

(2008) Austin L. Hughes et al.   IMMUNOGENETICS

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models

(2008) L. G. Burdelya et al.   SCIENCE

Role of neutrophils in BCG immunotherapy for bladder cancer

(2008) Mark P. Simons et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE